Obtenga las últimas noticias sobre las acciones de Adaptimmune Therapeutics con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de ADAP

Últimas noticias sobre

ADAPTIMMUNE THERAPEUTICS-ADR

Adaptimmune Therapeutics

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADAP

AGMH

AIIO

ASST

ATCH

ATMV

CEVA

FTHM

KAPA

LASE

MGIH

RNAZ

RVPH

SCHL

SOWG

VTEX

XXII

Las acciones de FedEx (FDX) suben un 5%; Aquí están 20 acciones que se mueven en el pre-market de EE.UU.

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics PLC

ADAPad

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies Corp

AdaptHealth Corp

Adaptive Hedged Multi-Asset Income ETF

Adaptive Alpha Opportunities ETF

ADAPTIVE AD SYSTEMS INC by Adaptive Ad Systems, Inc.

Adaptive Ad Systems Inc

Adaptive Core ETF

Adappter Token

Adapti Inc

Press Releases

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Adaptimmune Provides Q4 and Full Year 2024 Business Update

Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

Adaptimmune Reports Q1 Financial Results and Provides Business Update

Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds

Adaptimmune Reports Q2 Financial Results and Provides Business Update

AFFX

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

AlphaTON Capital

BioAtla

Dyadic International, Inc. - Common Stock

Dyadic International

Elutia

Equillium

FibroGen

Generation Bio

IO Biotech

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Liminatus Pharma, Inc. - Class A Common Stock

Liminatus Pharma

Lantern Pharma

LAVA Therapeutics

MAIA Biotechnology

Medicus Pharma

Mural Oncology

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

Pluri

Q32 Bio

RenovoRx

Skye Bioscience

Xilio Therapeutics

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock

Comments

Adaptimmune Therapeutics Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL